Truven Blog
Welcome to our blog where you can be informed about the latest health and technology insights.
Filters
Showing results for
Cell and gene therapy benefits planning: Using data to assess risk
Key takeaways:
From claims to clarity: Using MarketScan for stronger real-world evidence
In our webinar earlier this month, we discussed how MarketScan is more than a family...
3 ideas from the Truven Summit shaping the future of health and benefits
Last week in Nashville, we hosted the Truven Summit. Health and benefits leaders...
Lessons learned from a Biodesix and MarketScan custom data linking project
As real‑world data (RWD) becomes a central pillar of evidence generation, the...
Data & Analytics as a Service (DAaaS) in healthcare: Speed, scale, and sustainable insight
The story at a glance:
The rising cost of healthcare: Predicting high-cost claimants with AI-driven insights
For the fourth year in a row, commercial payers are bracing for continued increases...
Truven 2026 trends: What’s new with GLP-1s, gene therapy, and mental health
It’s a familiar theme at this point: healthcare costs are again expected to rise in...
How are university benefits teams managing GLP-1 coverage?
GLP-1 coverage management is a complex landscape, requiring a multifaceted strategy...
How MarketScan data informs flu prevention strategies
Last week was National Influenza Vaccination Week (NIVW), and it is an important...
Niche vs. enterprise analytics: Choosing the right path for healthcare success
Healthcare organizations are awash in data—from clinical records to operational...